Osmoprep generic
Osmoprep is an oral medication owned by Salix Pharmaceuticals. This drug contains active ingredients Sodium Phosphate, Dibasic, Anhydrous and Sodium Phosphate, Monobasic, Monohydrate. It was first authorized for market use on March 16, 2006.
When will Osmoprep generic be available?
The generic version of Osmoprep is expected to be released after June 22, 2028. This date corresponds to the expiration of the patent US7687075 titled 'Colonic purgative composition with soluble binding agent.'
Osmoprep uses
Available in tablet form, Osmoprep is used primarily as a colonic purgative. Its active ingredients, Sodium Phosphate, Dibasic, Anhydrous and Sodium Phosphate, Monobasic, Monohydrate, work together to increase water in the intestine to support bowel movements.
Osmoprep patent expiration
Osmoprep holds a single patent, designated as US7687075. This patent, which is titled 'Colonic purgative composition with soluble binding agent,' will expire on June 22, 2028, making an Osmoprep generic potentially available after this date. Below are the details of the patent: